Royalty Pharma plc (NASDAQ:RPRX) EVP Marshall Urist Sells 23,333 Shares of Stock

Royalty Pharma plc (NASDAQ:RPRXGet Rating) EVP Marshall Urist sold 23,333 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $39.85, for a total value of $929,820.05. Following the completion of the transaction, the executive vice president now directly owns 46,667 shares of the company’s stock, valued at $1,859,679.95. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

NASDAQ RPRX opened at $40.26 on Tuesday. The stock has a market cap of $24.44 billion, a PE ratio of 40.26, a P/E/G ratio of 1.09 and a beta of 0.36. The company has a current ratio of 21.95, a quick ratio of 21.95 and a debt-to-equity ratio of 0.70. Royalty Pharma plc has a twelve month low of $34.86 and a twelve month high of $47.10. The stock has a fifty day simple moving average of $40.51 and a 200-day simple moving average of $39.98.

Royalty Pharma (NASDAQ:RPRXGet Rating) last released its quarterly earnings results on Tuesday, February 15th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $543.00 million during the quarter, compared to analysts’ expectations of $543.50 million. Royalty Pharma had a return on equity of 16.75% and a net margin of 26.46%. During the same period in the prior year, the business posted $0.28 EPS. Research analysts predict that Royalty Pharma plc will post 3 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 15th. Stockholders of record on Friday, May 20th will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.89%. The ex-dividend date is Thursday, May 19th. Royalty Pharma’s dividend payout ratio is presently 76.00%.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RPRX. Morgan Stanley grew its holdings in shares of Royalty Pharma by 12.8% during the 3rd quarter. Morgan Stanley now owns 57,305,311 shares of the biopharmaceutical company’s stock worth $2,071,013,000 after purchasing an additional 6,511,270 shares during the period. BlackRock Inc. grew its holdings in shares of Royalty Pharma by 50.3% during the 3rd quarter. BlackRock Inc. now owns 15,460,845 shares of the biopharmaceutical company’s stock worth $558,754,000 after purchasing an additional 5,173,204 shares during the period. Norges Bank purchased a new position in Royalty Pharma during the 4th quarter valued at about $117,966,000. Marathon Asset Mgmt Ltd purchased a new position in Royalty Pharma during the 4th quarter valued at about $89,357,000. Finally, Vanguard Group Inc. boosted its holdings in Royalty Pharma by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 31,860,621 shares of the biopharmaceutical company’s stock valued at $1,241,289,000 after acquiring an additional 2,224,056 shares during the period. Institutional investors and hedge funds own 51.68% of the company’s stock.

Several research analysts recently commented on RPRX shares. Zacks Investment Research downgraded Royalty Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. StockNews.com started coverage on Royalty Pharma in a research note on Thursday, March 31st. They issued a “hold” rating for the company. JPMorgan Chase & Co. raised Royalty Pharma from a “neutral” rating to an “overweight” rating and set a $50.00 price objective for the company in a research note on Thursday, April 14th. They noted that the move was a valuation call. Morgan Stanley raised Royalty Pharma from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $46.00 to $48.00 in a research note on Wednesday, April 6th. Finally, Scotiabank began coverage on Royalty Pharma in a research note on Friday. They issued an “outperform” rating and a $53.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $49.43.

About Royalty Pharma (Get Rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Featured Articles

Insider Buying and Selling by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.